For consumer-directed plan members, fewer prescriptions

Share this article:
Study shows sample-drug adherence link
For consumer-directed plan members, fewer prescriptions

Eighty percent of US prescriptions are filled with generic drugs, but a recent study by the Employee Benefit Research Institute shows that generic fill data, which is often used to promote the cost-savings associated with generic drugs, may hide the impact some health insurance plans have on patient medication use.

The study tracked prescription use among employees of an unnamed company from 2006 through 2010, the point at which the company moved all of its employees to a consumer-directed health plan, often referred to as a CDHP.

The appeal to employers of these plans is that they expose employees to a greater portion of the cost of medical services, an experience expected to prompt the insured to shop for medical treatments much as they would for everyday items, such as cars, washing machines or even clothing. The plans achieve this with a high deductible, so that the insured need to either sign on for one high-priced service, or multiple small ones before being eligible for a lower-cost experience through their insurer.

These plans also affect prescriptions, and it is here that the institute found that employees filled fewer prescriptions—not just fewer brand name prescriptions, but fewer generic and brand prescriptions—the longer they were covered by a CDHP plan.

They also found that this same drop made the number of filled generics appear higher, because the Generic Dispensing Rate metric rises under two scenarios: if the number of dispensed generics goes up, or if the total number of drug fills falls.

Researchers point out that this may be a short-term win for employers because lower prescription use “increases in downstream medical costs,” which “may eclipse those benefits.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...